November 15, 2018 10:09 AM EST

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod

ENDPOINTS

→ The non-opioid painkiller developer Centrexion, which is led by former Pfizer $PFE chief Jeffrey Kindler, has reportedly postponed its IPO. The Boston-based company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Cen­trex­ion de­lays IPO; Ex­elix­is makes $40M as Cabome­tyx wins EU nod

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod